secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-068543
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd launches discovery program for measles monoclonal antibody; candidate target by 2025
--------------------------------------------------------------------------------

- Multiple healthcare providers have requested a monoclonal antibody for measles treatment and post-exposure prophylaxis from Invivyd.
- Goal is to identify a preclinical measles mAb candidate in 2025; progress update expected by end of year.
- Over 20 million Americans are unvaccinated; U.S. at risk of losing functional elimination as vaccination rates decline.
- No approved therapies currently exist for measles; current options include high-dose Vitamin A and IVIG, both with limitations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/0000950170-25-068543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/ivvd-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer